Goldman Sachs
NMRD

Goldman Sachs’s Nemaura Medical, Inc. Common Stock NMRD Stock Holding History

Goldman Sachs’s Portfolio NMRD Stock Details NMRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-22,549
Closed -$209K – 5591
2020
Q2 		$209K Buy
+22,549
New +$161K ﹤0.01% 4779

Other funds holding NMRD

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Goldman Sachs's NMRD Position: Q3 2020 in Review

Goldman Sachs sold out of Nemaura Medical, Inc. Common Stock (NMRD) in Q3 2020, closing a stake of 22,549 shares — an estimated $209K sold.

Goldman Sachs first reported a position in NMRD in Q2 2020 and held it in 1 quarter. The position peaked at $209K in Q2 2020. 30 funds tracked by Wall St. Rank hold NMRD as of Q3 2020.

  • Goldman Sachs reported no remaining Nemaura Medical, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Goldman Sachs sold 22,549 Nemaura Medical, Inc. Common Stock shares in Q3 2020, an estimated $209K.
  • Goldman Sachs first reported a position in Nemaura Medical, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • Goldman Sachs's Nemaura Medical, Inc. Common Stock position peaked at $209K in Q2 2020.
  • 30 funds tracked by Wall St. Rank held Nemaura Medical, Inc. Common Stock as of Q3 2020.

Based on Goldman Sachs's 13F filing for Q3 2020, filed 13 Nov 2020.